EpimAb to Present Late-breaking Abstract on Preclinical Results of EMB-07
EpimAb to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference
SHANGHAI, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer (CMO). As CMO, Dr. Zhu will be responsible for overseeing all clinical development activities for the company’s clinical stage assets. This strategic addition to the executive team further strengthens the company's commitment to innovation and mission of advancing cutting-edge bispecific therapies. Dr. Zhu replaces EpimAb’s previous CMO, Dr. Bin Peng, who recently retired from EpimAb after five years of service at the company.
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients with non-small cell lung cancer (NSCLC) evaluating the combination of EMB-01, a bispecific antibody designed to simultaneously target EGFR and cMET on tumor cells, and Tagrisso® (osimertinib), AstraZeneca’s (LSE/STO/Nasdaq: AZN) third-generation EGFR-TKI. AstraZeneca is providing Tagrisso® for this trial under a non-exclusive clinical trial collaboration agreement.
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Zhu is internationally recognized as a leading authority in hepatocellular carcinoma and cholangiocarcinoma and brings decades of research and clinical expertise. He has served on the Advisory Boards of many biotech and pharma companies and is currently a Professor of Medicine at Harvard Medical School and Chief Scientific Officer at Jiahui Health.
EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients with advanced solid tumors, as well as in a Phase 1/2 clinical trial of EMB-06, a bispecific antibody targeting B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), in patients with recurrent and refractory multiple myeloma. The company also announced the approval of its Investigational New Drug (IND) application for EMB-02 by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).
SHANGHAI--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120 million Series C financing round. The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital. Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics. Tony Rong, nominated by CMBI, and Sungwon Song, nominated by Mirae, will also join the EpimAb Board of Directors.